The second and final installment of our discussion focuses on the use of stem cells and what further research is on the horizons for multiple sclerosis.
Browsing: demyelinating disease
Ask the Experts: Emerging therapies in multiple sclerosis (Part I: mechanisms, therapies and challenges)
In the first installment of this discussion, our experts discuss the mechanisms, therapies and challenges involved in multiple sclerosis research.
To mark World Multiple Sclerosis Day, we’re taking the opportunity to look back on some of the highlights in the field so far this year.
Alexander Rae-Grant chats to Lauren Pulling about the new guideline for multiple sclerosis treatment and how it will affect treatment practice in the field.
Results from the Phase III EXPAND study of siponimod in secondary progressive multiple sclerosis have been announced, revealing that the drug reduced the risk of disability progression.
Analysis of three studies looks at the role of octagam® for chronic inflammatory demyelinating polyneuropathy patients
Editor’s summary considering the effectiveness and tolerability of octagam in patients with chronic inflammatory demyelinating polyneuropathy.
Advancing the understanding of progression in multiple sclerosis: an interview with Shibeshih Belachew
In this interview from Neurodegenerative Disease Management, hear from Shibeshih Belachew (Roche) on the future of multiple sclerosis trials and therapeutics.
Researchers discover latent human herpes virus 6 may interfere with the brains ability to repair damaged myelin in brain diseases such as multiple sclerosis.
Researchers highlight Rab32 as a potential cause and treatment target for multiple sclerosis.
A small, preliminary study investigating the relationship between multiple sclerosis and the Epstein-Barr virus suggests a potential novel treatment for progressive multiple sclerosis.